Table 2.

Details of MCS therapy.

Parameter	Group 1 (n=30)	Group 2 (n=33)	p-value
Indication for ECLS
Acute myocardial infarction	12 (40)	12 (36)	0.767
Ischemic cardiomyopathy	1 (3)	3 (9)	0.349
Non-ischemic cardiomyopathy	7 (23)	5 (15)	0.409
Myocarditis	1 (3)	4 (12)	0.197
Post-cardiotomy shock	5 (17)	6 (18)	0.874
Post-transplant graft dysfunction	4 (13)	3 (9)	0.593
ECPR	10 (33)	5 (15)	0.091
Bridge to ventricular assist device	1 (3)	3 (9)	0.349
Bridge to heart transplant	0	2 (6)	0.171
Duration of VA-ECMO support, days	4.97 ± 5.10	6.55 ± 4.89	0.215
Duration of MCS support, days	5.45 ± 5.37	8.45 ± 7.82	0.087
Peripheral cannulation strategy	23 (77)	23 (70)	0.534

Values presented as number (percentage) or mean ± standard deviation.